AngioDynamics, Inc. (NASDAQ:ANGO) Files An 8-K Regulation FD Disclosure

AngioDynamics, Inc. (NASDAQ:ANGO) Files An 8-K Regulation FD Disclosure
Item 7.01 – Regulation FD Disclosure.

Presentation slides discussing AngioDynamics, Inc. (“AngioDynamics”) and its fiscal fourth quarter and full year ended May 31, 2019 are being furnished herewith as Exhibit 99.1. The slides are being furnished to Item 7.01 and the information contained therein shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities under that Section. Furthermore, the information in Exhibit 99.1 shall not be deemed to be incorporated by reference into the filings of AngioDynamics under the Securities Act of 1933, as amended.
Item 9.01 – Financial Statements and Exhibits.
(d) Exhibits.
ANGIODYNAMICS INC Exhibit
EX-99.1 2 an53922086-99_1.htm PRESENTATION DATED JULY 10,…
To view the full exhibit click here

Story continues below

About AngioDynamics, Inc. (NASDAQ:ANGO)

AngioDynamics, Inc. designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures. The Company offers products within three product groupings: Peripheral Vascular, Vascular Access and Oncology/Surgery. The Company’s Peripheral Vascular products include Fluid Management, Venous, Thrombus Management, as well as other core products. The Company’s BioFlo products incorporate Endexo Technology into the manufacturing and design of its Vascular Access products. Its Oncology/Surgery product offerings include its Microwave Ablation products, Radiofrequency Ablation (RFA) and its NanoKnife product lines.

An ad to help with our costs